

[illegible]

[illegible]

**FIGURE 3**

CV-1/131A

## **DMEM serum free bioreactors**

**YM30 Spiral cartridge conc.**

add ammonium sulfate  
HEPES pH 8.5

Phenyl Sepharose CL-4B

**0.2M ammonium sulfate  
20 mM HEPES pH 8.5  
elute with 10mM HEPES pH 8.5**

**add NaCl to 1.6 mS/cm**

DEANE Sephacel

10mM HEPES pH 8.5  
0.14 to 0.3 M NaCl gradient

**dilute to 1.2 mS/cm**

## Motto 2

10mM HEPES pH 8.5  
0.1 to 0.5 M NaCl gradient

III'LC C4 reverse phase (Vydac, 46 X25 cm, 5μ)  
0.1% TFA to 0.1% TFA/100% AcN, 1ml/min

0 to 45% AcN 1%/min  
45-60% AcN 0.5%/min  
60-100% AcN 2%/min

HPLC C4 reverse phase (Vydac, 46X25cm, 5u)  
0.1% TFA to 0.1% TFA/60% n-propanol  
0.5ml/min  
0.5%/min gradient

**SDS PAGE: 14% reducing**

**1971**

### N-terminal protein sequence

ATGAGAAATTTCGAAACCAATTTGAAGAAATTTCCATCCAGTGCCTAACCT  
ATGAGAAATTTCGAAACCAATTTGAAGAAATTTCCATCCAGTGCCTAACCT  
GTGTTTAACTTCTAAACAAGTCAATTTCTAAACCTGAAGCTGCATTCATGCTCT  
GTGTTTAACTTCTAAACAAGTCAATTTCTAAACCTGAAGCTGCATTCATGCTCT  
TCATTTTGGGCTGTTTCAAGTCCAGGGCTCCCTAAACAAGAAAGCCAACTGG  
TCATTTTGGGCTGTTTCAAGTCCAGGGCTCCCTAAACAAGAAAGCCAACTGG  
GTGAATGTAATGAATGGAAATGAATGAATGAATGAATGAATGAATGAATGAAT  
GCATATGTAATGTAATGAATGAATGAATGAATGAATGAATGAATGAATGAAT  
GCATATGTAATGTAATGAATGAATGAATGAATGAATGAATGAATGAATGAAT  
AGTAAACAAGCAATGAAGTCTTCTGGAAGTTCACAAAGTTTATTCACAT  
GAGTCCGGAATGCAAGTATGATACAGTAAAGTAATTCGATCATCTCT  
GAGTCCGGAATGCAAGTATGATACAGTAAAGTAATTCGATCATCTCT  
AGCAAAACAAGTTCGTTCTAAATGGGAATGAATGAATGAATGAATGAATGAAT  
AGCAAAACAAGTTCGTTCTAAATGGGAATGAATGAATGAATGAATGAATGAAT  
AAGAAATGTCGAGCACTGCGAGAAATAATAAGAAATTTTTCGAGAGT  
AAGAAATGTCGAGCACTGCGAGAAATAATAAGAAATTTTTCGAGAGT  
TTTGTAATATGTCCTCAATCACTTCGA

FIGURE 4

$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) e^{-x^2} dx = \frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) e^{-x^2} dx$

FIGURE 5

1	MRISKPHLRSISIQCYLCLLNSHFLTEAGIHVFILGCF SAGLPKTEANW	50
1	MRISKPHLRSISIQCYLCLLNSHFLTEAGIHVFILGCF SAGLPKTEANW	50
51	VNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCF LLELQVISL	100
51	VNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCF LLELQVISL	100
101	ESGDASIHDIVENLIILANNSSLSSNGNVTESGCKECEELEKNIKEFLQS	150
101	ESGD'DIHDIVENLIILANNSSLSSNGNITESGCKECEELEKNIKEFLQS	150
151	FVHIVQMFINTS* 163	
151	FVHIVQMFINTS* 163	

FIGURE 6




FIGURE 7




FIGURE 8






FIGURE 9




FIGURE 10

